CAJ | 학술논문

HCV感染与多种重要的肝脏疾病相关，经典的治疗方法为聚乙二醇干扰素（pegylated interferon, Peg-IFN）α联合利巴韦林。虽然此疗法在约60%的慢性丙型肝炎患者中可获得良好的临床疗效及持久病毒学应答，但由于造血系统和神经细胞的不良反应而限制了其广泛应用。目前，一个新发现的IFN家族：Ⅲ型IFN，即IFN λ（包括IFN λ1、IFN λ2和IFNλ3），又称白细胞介素（interleukin, IL）-29、IL-28A和IL-28B，在抗病毒治疗方面较Peg-IFNα有一定优势。基因组学研究也发现，IFNλ的基因多态性与慢性HCV感染治疗预后相关。本文主要对IFNλ的生物学功能及其在抗HCV治疗中的应用前景进行综述。
HCV감염여다충중요적간장질병상관，경전적치료방법위취을이순간우소（pegylated interferon, Peg-IFN）α연합리파위림。수연차요법재약60%적만성병형간염환자중가획득량호적림상료효급지구병독학응답，단유우조혈계통화신경세포적불량반응이한제료기엄범응용。목전，일개신발현적IFN가족：Ⅲ형IFN，즉IFN λ（포괄IFN λ1、IFN λ2화IFNλ3），우칭백세포개소（interleukin, IL）-29、IL-28A화IL-28B，재항병독치료방면교Peg-IFNα유일정우세。기인조학연구야발현，IFNλ적기인다태성여만성HCV감염치료예후상관。본문주요대IFNλ적생물학공능급기재항HCV치료중적응용전경진행종술。
HCV infection is associated with many major liver diseases. The current standard-of-care therapy for HCV infection is a combination of pegylated interferon (Peg-IFN) α and ribavirin. Although the therapy effectively generates a sustained virological response in approximately 60% of the treated patients with chronic hepatitis C, the obvious hematological and neurological adverse reactions limit its extensive use. Nowadays, a new IFN family, named as type Ⅲ IFN or IFN λ(including IFNλ1, 2, and 3; or alternately, interleukin-29, 28A and 28B, respectively) possesses properties that may make these cytokines superior to Peg-IFN α for HCV treatment. Genetic studies have also revealed that the single nucleotide polymorphisms of these proteins were also correlated with the prognosis of the treatment of chronic HCV infection. This review summarizes the biological functions of IFNλand the outlook for its therapeutic application in HCV infection.